Registration for is no longer available. To order your PeproTech products online, register or logon to

Antigen Affinity Purified Polyclonal Antibodies

Anti-Human VEGF165 (Polyclonal Rabbit)

0 ReviewsSubmit a Review

Product Details

Catalogue Number: 500-P10
Anti-Human VEGF 165 (Polyclonal Rabbit)

Source: Polyclonal Rabbit

Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human VEGF 165. Anti-Human VEGF 165-specific antibody was purified by affinity chromatography employing an immobilized Human VEGF 165 matrix.

Immunogen: E.coli derived Recombinant Human VEGF165 (PeproTech catalog# 100-20)

Sandwich ELISA: To detect hVEGF by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech’s Biotinylated Anti-Human VEGF (500-P10Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hVEGF.

Anti-Human VEGF 165 Sandwich ELISA

Western Blot: To detect hVEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hVEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

Anti-Human VEGF 165 Western Blot Reduced	Anti-Human VEGF 165 Western Blot Unreduced


Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information.

Country Of Origin: USA

Not for human use.

Research Interest


First Author
Hamilton, B J
Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner.
Journal of Cellular and Molecular Medicine; 23(2) pg920-933
PubMed Id
First Author
Meda, C
Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages.
Journal of immunology (Baltimore, Md. : 1950); 188(8) pg4081-92
PubMed Id
First Author
Bottos, A
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.
Proceedings of the National Academy of Sciences of the United States of America; 109(6) pgE353-9
PubMed Id